| Filed On | Filing |
|---|---|
| 07 Feb 2017 |
8-K/A: Completion of Acquisition or Disposition of Assets
We have audited the accompanying consolidated financial statements of Kolltan Pharmaceuticals, Inc. and its subsidiaries (the “Company”), which comprise the consolidated balance sheets as of December 31, 2014 and 2015 and the related con... |
| 21 Oct 2009 |
8-K/A: Completion of Acquisition or Disposition of Assets
QuickLinks -- Click here to rapidly navigate through this document |
| 06 Nov 2008 |
8-K/A: Results of Operations and Financial Condition
NEEDHAM, MA (November 5, 2008): Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine-month period ended September 30, 2008. Celldex reported a net loss of $7.7 million, or $0.49 per sh... |
| 23 May 2008 |
8-K/A: Completion of Acquisition or Disposition of Assets
We consent to the use of our report dated May 7, 2008, with respect to the consolidated financial statements of Celldex Therapeutics, Inc. and Subsidiary, included in this Current Report on Form 8-K/A of AVANT Immunotherapeutics, Inc., f... |
| 03 Jul 2001 |
8-K/A: Financial Statements and Exhibits
Financial statements of Megan Health, Inc. were previously filed with Form 8-K/A as Attachment A on January 30, 2001. |
| 30 Jan 2001 |
8-K/A: Financial Statements and Exhibits
As independent public accountants, we hereby consent to the incorporation of our report included in this Form 8-K/A, into previously filed Registration Statements on Forms S-8, (Nos. 333-34780, 333-43640, 333-52795, 333-54372, 333-80036,... |
| 29 Sep 1998 |
8-K/A: Other Events
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Loading...